-
South Korean survivor fights for workplace harassment 'justice'
-
Messi scores but Miami slump continues with loss to Toronto
-
Starc strikes as Bangladesh struggle to stay alive in 2nd Test
-
Sydney marathon unveils medal with wrong stadium
-
Prince Harry: royal misfit making unlikely UK return
-
Macron hosts Saudi's MBS for visit ranging from esports to Mideast
-
Blowing in the wind, humble balloon gets green makeover
-
Australia in control with 146-run first innings lead over Bangladesh
-
Pegula dethrones Swiatek to reach Cincinnati final
-
World No. 3 Pegula beats defending champ Swiatek to reach Cincy final
-
IndyCars zip among iconic Washington landmarks ahead of Freedom 250
-
Wyndham Clark surges clear at BMW Championship
-
Real Madrid snatch late win at Espanyol on Mourinho's return
-
Maresca says Man City must fill Rodri void after Barca switch
-
Real Madrid beat Espanyol in Mourinho's first game on return
-
Canada retaliates as trade war with US escalates
-
Olise helps Bayern past Dortmund in German Supercup
-
Fils dominates Cobolli to book Cincinnati final
-
Coach Rennie hails clinical All Blacks after Springboks Test win
-
Spurs lacked fight in dismal defeat at Brentford says De Zerbi
-
Charlton deliver blow to 'under pressure' Hammers boss Nuno
-
Inter thrash Monza to launch Serie A title defence
-
Carrick keeps calm despite Man Utd misery, big-spending Spurs crushed
-
Shambolic Spurs battered by Brentford
-
Canada's Carney stands up to Trump, despite risks
-
Pogacar wins Vuelta a Espana opening stage
-
Lens hammer Auxerre thanks to Thauvin penalty double
-
Clinical New Zealand shock wasteful South Africa in first Test
-
No singles for Serena, but she joins Alcaraz for US Open
-
Canada hits back with new tariffs after trade talks with US fail
-
Joao Pedro extends Chelsea stay with new long-term deal
-
Swedish police identify 17-year-old girl as victim in school sword attack
-
Yamaguchi to face An in hunt for fourth badminton world crown
-
Carrick keeps calm despite Man Utd misery, Sage beaten in first game as Palace boss
-
Norris clinches pole for Dutch GP
-
France to deliver interceptor missiles to Ukraine after new Russian strikes
-
Norris clinches pole for Dutch Grand Prix
-
Serena Williams and Alcaraz unite in US Open mixed doubles
-
Pope Leo calls for courage in Rimini visit after stop in tiny San Marino
-
Macron pledges air defence as 13 killed in Russia, Ukraine strikes
-
Man Utd must learn from 'frustrating' defeat at Hull: Carrick
-
DR Congo capital wary of Ebola nightmare
-
Yamaguchi on course for fourth badminton world crown
-
Swedish police name 17-year-old girl as victim in school sword attack
-
Man Utd humiliated by Hull in dismal start to Premier League season
-
South Korea sends first container ship through Arctic route
-
Anthropic market debut could break SpaceX IPO record: media
-
Trescothick eager to keep England job despite Hussey approach
-
Pope's 'couturier of the sacred' fueled by faith
-
Indonesia deploys hundreds of soldiers to tackle Borneo fires
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=135012&wire=1
or contact Joseph E. Levi, Esq. via email at [email protected] or call (212) 363-7500 to speak to our team of experienced shareholder advocates.
THE LAWSUIT: A class action securities lawsuit was filed against Regeneron Pharmaceuticals, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Regeneron paid credit card fees to distributors on the condition that distributors did not charge, one of the Company's primary products, Eylea customers more to use a credit card; (2) these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (3) as a result, Regeneron offered a price concession that lowered Eylea's selling price; (4) because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron's price concessions provided a competitive advantage; (5) as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales; (6) by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
WHAT'S NEXT? If you suffered a loss in Regeneron stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=135012&wire=1 to learn about your rights to seek a recovery. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire
D.Qudsi--SF-PST